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Conventional hepatic arterial infusion chemotherapy (HAIC), 
consisting of 5-fluorouracil (5-FU) and cisplatin delivered via im-
planted chemoport every 4 weeks, is a form of regional to system-
ic chemotherapy to treat unresectable or advanced hepatocellular 
carcinoma (HCC). The idea of localized infusion of cytotoxic agents 
into liver originated from hepatic metastasis of colorectal cancer.1 
It is interesting that the first application of HAIC to HCC has been 
done in Western country,2,3 even though that modality is now be-
ing used in Japan, Korea and Taiwan. In a Japanese retrospective 
study of 48 patients with portal vein tumor thrombosis, the objec-
tive (complete and partial) response rates were high (48%) and 
3-year survival rates were 25%.4 In a large Japanese cohort, the 
median survival times of patients who underwent HAIC was 14.0 
months, which were significantly higher than in those who did not 
receive active treatment (5.2 months, P<0.0001).5 In contrast with 
daily, low doses of cisplatin (7 mg/m2 on day 1-5) and 5-FU (170 
mg/m2 on day 1-5) in Japanese practice, Korean regimen consisted 
of higher cisplatin (60 mg/m2 on day 2) and 5-FU (500 mg/m2 on 
day 1-3) doses repeated every 4 weeks.6,7 The dictionary meaning 
of ‘metronome’ is a device that produces regular, metrical ticks or 
beats; these represent a fixed, regular pulse. In the current issue 
by Yang et al.8, 1 cycle of metronomic chemotherapy (MET) was 
composed of single low doses of cisplatin (15 mg/m2) and 5-FU 
(50 mg/m2) infused via hepatic arterial infusion chemoport for 
3 weeks (1 week break).8 The authors aimed to retrospectively 
compare the efficacy and safety between MET and sorafenib in 
patients with advanced (BCLC-C) stage. In 54 and 53 patients 
who received MET and sorafenib treatment, the median overall 
survival (OS) was 158 and 117 days, respectively (P=0.029). The 
disease control rate assessed at week 8 tended was higher in MET 
group than in sroafenib group (53.7% vs. 22.0%; P=0.014). In 
subgroup of patients with Child-Pugh class B, the median OS was 
significantly longer in MET group than in sorafenib group (190 
vs. 58 days, P<0.001). In terms of safety, although there is no 
information on the proportion of treatment discontinuation due to 
adverse events (AEs), MET was more related to hematologic AE 
including leukopenia and thrombocytopenia, whereas the majority 
of sorafenib-related toxicity was hand foot skin reaction and AE 
of gastrointestinal tract. Based on these results, the authors state 
that MET would be an alternative to sorafenib in HCC patients 
with BCLC-C stage, particularly if they don’t have preserved liver 
function.
This article by Yang et al.8 suggests that MET, a sort of regional 
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cytotoxic chemotherapy, might be a potential option for advanced 
HCC. The MET seems to have an advantage of lower rates of tox-
icity such as hepatic decompensation compared with conventional 
HAIC. In addition, there seems to be no need of hospitalization 
for drug administration. However, the study has several limita-
tions. Apart from the retrospective nature of data, sample size 
is not enough to draw the conclusion that MET is comparable to 
sorafenib. Most importantly, the variables are imbalanced be-
tween the two groups. Although there was no significant statisti-
cal difference, more patients in sorafenib group had main portal 
vein tumor thrombosis than in MET group (45.3% vs. 33.3%). 
The frequency of extrahepatic metastasis, which is an important 
prognostic factor, was also higher in sorafenib group than in MET 
group (66.0% vs. 51.9%, P=0.136).
Though the role and positioning of HAIC, including MET, has 
not yet been established in HCC, a recently published paper re-
porting the efficacy of sorafenib plus HAIC suggests a possibility 
of combining systemic therapy and regional cytotoxic chemother-
apy to enhance anti-tumor effect. In the Japanese prospective, 
multicenter trial, a total 108 patients with advanced HCC were 
randomized to sorafenib group and sorafenib plus HAIC group (in-
fusion of only cisplatin). The median survival times were 8.7 and 
10.6 months, respectively (P=0.031). The response rate was 7.3% 
in sorafenib group and 21.7% in combination group.9
For HAIC to be widely accepted as a modality for HCC, more 
scientific evidences should be accumulated. The deterioration of liver 
function encountered with repeated cycles of HAIC is a major con-
cern. In this regards, lower probability of liver toxicity by MET is obvi-
ously a merit, if we can guarantee that the efficacy of MET is similar 
to conventional HAIC. With few available regimens for patients with 
sorafenib failure except regorafenib, HAIC including MET also needs 
to be further evaluated as a second-line modality.10,11
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